Supplementary data

Table 3. More specific indications for primary THA (includes only patients operated in years 2014–2017). Values are count (%)

| Diagnosis                  | DMC (Trident) n = 306 | DMC (Others) n = 134 | CL < 36 mm n = 185 | CL 36 mm n = 203 | Conventional THA n = 34,557 |
|---------------------------|-----------------------|----------------------|-------------------|-----------------|-----------------------------|
| Osteoarthritis            | 188 (61)              | 50 (37)              | 62 (34)           | 53 (26)         | 29,218 (85)                 |
| Hip fracture              | 84 (27)               | 68 (51)              | 60 (32)           | 34 (17)         | 1,748 (5.1)                 |
| Avascular caput necrosis  | 17 (5.6)              | 6 (4.5)              | 6 (4.3)           | 4 (2.0)         | 953 (2.8)                   |
| Developmental dysplasia of the hip | 2 (0.7) | –                    | 3 (1.6)           | 3 (2.2)         | 503 (1.5)                   |
| Failed osteosynthesis after hip fracture | 2 (0.7) | 2 (1.5) | 23 (12) | 14 (6.9) | 53 (0.2) |
| Secondary osteoarthritis after hip fracture | – | 1 (0.7) | 1 (0.5) | 5 (2.5) | 100 (0.3) |
| Inflammatory joint disease | 3 (1.0)               | 3 (2.2)              | –                 | –               | 550 (1.6)                   |
| Pyrulent arthritis        | –                     | –                    | 1 (0.5)           | –               | 12 (0.03)                   |
| Childhood joint disease   | –                     | –                    | –                 | –               | 108 (0.3)                   |
| Tumor                     | –                     | 1 (0.7)              | 4 (2.2)           | 65 (32)         | 41 (0.1)                    |
| Other disease             | 1 (0.3)               | –                    | 10 (5.4)          | 8 (3.9)         | 169 (0.5)                   |
| Data missing              | 9 (2.9)               | 3 (2.2)              | 14 (7.6)          | 16 (7.9)        | 1,102 (3.2)                 |

Table 5. Cumulative incidence function estimates at 1, 3, and 6 years of first revision and death with 95% confidence intervals for the CL < 36 mm group stratified by the femoral head size

| Risk of revision | CL 22 mm n = 64 | CL 28 mm n = 111 | CL 32 mm n = 127 |
|------------------|-----------------|------------------|------------------|
| 1 year           | 11 (3.2–19)     | 10 (4.3–16)      | 8.0 (3.2–13)     |
| 3 years          | 13 (4.4–21)     | 14 (6.8–20)      | 14 (7.1–21)      |
| 6 years          | 13 (4.4–21)     | 14 (6.8–20)      | 14 (7.1–21)      |
| Risk of death    |                 |                  |                  |
| 1 year           | 9.4 (2.2–17)    | 6.5 (1.8–11)     | 9.1 (3.9–14)     |
| 3 years          | 27 (15–39)      | 17 (9.0–26)      | 17 (9.6–24)      |
| 6 years          | 42 (28–56)      | 31 (17–45)       | 37 (25–49)       |

Figure 3. Cumulative incidence function estimates of the first revision with death as competing event.